Efeito da terapêutica sulfônica na sobrevida dos doentes de hanseníase

JOSE MARIA MARLET

doi:10.47878/hi.1978.v3.36087

Authors

JOSE MARIA MARLET Professor Livre-Docente de Estatística, Livre-Docente de Medicina Preventiva e Professor Titular das Faculdades de Ciências Médicas da Pontifícia Universidade Católica de Campinas e de Medicina de Catanduva.

DOI:

https://doi.org/10.47878/hi.1978.v3.36087

Keywords:

Hanseniasis, Epidemiology, Outliving

Abstract

By utilizing the technique of outliving, modified to follow-up chronic diseases, the accumulated
probabilities of outliving of 5000 hanseniasis patients of the presulfonic era and of 5000 of the sulfonic era were studied. The probabilities of outliving were calculated accord- ing to the initial classification and the patient's age at the time of diagnosis. It was observed that: 1. Sulfone therapy increases the hanseniasis patients accumulated probabilities of outliving. 2. Virchowian patients are those who benefit most as regards outliving by sulfone therapy. 3. The growth of outliving supplied by sulfones to the tuberculoid patients is practically the same as that supplied to the indetermined.

Downloads

Download data is not yet available.

References

1. BALTES, P.B. Longitudinal and cross-sectional sequences in the study of age and generation effects. Hum. Develop., 11:145-171, 1968.
2. BELDA, W. Aspectos epidemiológicos da hanseniase no Estado de Silo Paulo, em 1974. Hansen. hit., 1(1) :11-24, 1976.
3. CHIANG, C.L. Stochastic study of the life table and its applications. Hum. Biol., 22:221-238, 1960.
4. CONOVER, W.J. Practical non parametric statistics New York, John Wiley, 1971.
5. DALLAS, J. Patient follow-up in a long-term study. Johns Hopkins Med. J., 128:244-521, 1971.
6. FLOOR, L.; BAXTER, D.; ROSEN, M. Subject loss in a follow-up study. Ment. Retard., 10:3-5, 1972.
7. GUINTO, R.S.; DOULL, J.A.; GUIA, L.; RODRIGUEZ, J.N. Mortality of persons with leprosy prior to sulphone therapy. Int. J. Leprosy, 22(3) :273-284, 1954.
8. HEDLEY, A.J. The use of a computer in patient follow-up in Scotland. Scott. Med. J., 15:395-399, 1970.
9. HOLZMAN, R.S. Proper statistics for clinical studies. Ann. Interm. Med., 75:649-656, 1971.
10. MARLET, J.M. & BELDA, W. Esperanças de sobrevida na hanseníase. Hansen. Int., 1 (2) :191-200, 1976.
11. MERRELL, M. & SCHULMAN, L.E. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J. Chron. Dis., .1:12-32, 1955.
12. NOORDEN, S.K. Mortality in leprosy. Indian J. Med. Res., 60(3) :439-445, 1972.
13. PASTERNACK, B.S. gi GILBERT, H.S. Planning the duration of long-term survival time studies designed for accrual by cohorts. J. Chron. Dis., 24:681-700, 1971.
14. PATEO JR., J.D. Da mortalidade e suas causas nos doentes de lepra. In: CONFERENCIA PANAMERICANA DE LEPRA, 2°, Rio de Janeiro, 1946. v. 3, p. 317-324.
15. QUAGLIATO, R.; BERQUÓ, E.; LESER, W. Lepromatosos em tratamento sulfônico.Rev. Bras. Leprol., 29: 19-30, 1961
16. SANTOS, J.L.F. Contribuigdo para o tratamento estoecistico da tábua de sobrevivência e suas aplicações. São Paulo, 1972. [Tese — Faculdade de Saúde Pública] 152 p.
17. SCHLESSELMAN, J.J. Planning a longitudinal study. J. Chron. Dis., 26:553-560, 1973.
18. SMALL, W.P. The long-term clinical follow-up of patients. Health Bull., Edinb., 29:22-26, 1971.
19. SOUZA-CAMPOS, N. Causa-mortis entre os doentes de lepra. Rev. Bras. Leprol., 4:69-79, 1936.
20. YBARRA PEREZ, R. & GONZALEZ PRENDES, M.A. Estudio comparativo de la supervivencia de los enfermos de lepra, antes y despues de emplearse los medicamentos sulfonados. Rev. Situ. Leprol. Dermatol., 14 (1):13-16, 1958.